argenx, a global immunology company, announced a webinar on June 23, 2026, focusing on autoimmune myositis, a disease causing progressive muscle damage. The event will highlight new insights into disease biology and discuss the ALKIVIA clinical program and the potential of efgartigimod as a treatment. This webinar is part of argenx's series showcasing its research and development strategy in autoimmune diseases. The webcast will be available on the argenx website for about a year.
The AI cryptocurrency sector reached a market cap of about $26.6 billion in May 2026, led by projects like Chainlink and NEAR Protocol. Ruvi AI (RUVI) stands out by integrating over 20 AI models into a decentralized platform that rewards contributors...
ImPact Biotech presented updated positive data from its Phase 1 trial for Padeliporfin VTP in locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) and Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (LG-UTUC) at ASCO 2026...
AIX Alpha has introduced a new AI-powered automated trading platform designed to help retail traders manage the increasing volatility in digital asset markets, particularly XRP. The system analyzes over 100,000 market signals daily and adjusts strate...
SpaceX is preparing for the largest IPO in history with its Starlink satellite network, targeting a valuation between $1.75 trillion and $2 trillion. This IPO will surpass previous tech giants' offerings by a huge margin and highlights the rapid grow...
Ethereum (ETH) has a significant liquidation risk zone at $1,921, where leveraged long positions on centralized exchanges could face forced liquidation totaling $781 million if the price drops below this level. This risk arises from a dense cluster o...
